elicited antibodies cannot bypass glycans present on the conserved position N276 of Env, which restricts access to the CD4-binding site. Efforts to guide the appropriate maturation of these antibodies by sequential immunization have not yet been successful. Here, we report on a two-step immunization scheme that leads to the maturation of VRC01-like antibodies capable of accommodating the N276 glycan and displaying autologous tier 2 neutralizing activities. Our results are relevant to clinical trials aiming to elicit VRC01 antibodies.
INTRODUCTION
VRC01-class antibodies are potent and broad HIV-1 neutralizing antibodies (bnAbs) that offer protection from experimental animal (S)HIV (simian HIV) infection (Balazs et al., 2014; Gautam et al., 2016; Pegu et al., 2014; Shingai et al., 2014) , and could be an important component of the protective immune responses elicited by an effective HIV-1 vaccine (Burton and Hangartner, 2016; Kwong and Mascola, 2018) . They have been isolated from several HIV-1-infected subjects and share key genetic origins: their heavy chain (HC) V genes are derived from the VH1-2*02 allele and are paired with light chains (LCs) expressing 5-amino acid (aa)-long CDRL3, which is rarely found in the human antibody repertoire. The 5-aa CDRL3 contains a hydrophobic residue at position 91 and a Glu96 (Scheid et al., 2011; Wu et al., 2010 Wu et al., , 2011 Zhou et al., 2013 Zhou et al., , 2015 . The VRC01-class bnAbs are extensively somatically hypermutated (up to 30% aa difference from germline) and can be up to 50% divergent in aa sequence (Scheid et al., 2011; Wu et al., 2010 Wu et al., , 2011 Zhou et al., 2010 Zhou et al., , 2015 . Despite this marked diversity, their CDR domains adopt similar overall structures and recognize the CD4-binding site (CD4-BS) of Env in a manner similar to that of CD4 . Thus, despite their similar genetic origins, during chronic infection with different HIV-1 viruses, VRC01-class antibodies mature along different pathways but ultimately adopt similar structures that are associated with their broad neutralizing activity. The "structural convergent evolution" observed during natural HIV-1 infection suggests that more than one evolutionary pathway will be available to develop VRC01-class bnAbs by immunization.
Longitudinal natural viral Env variants associated with the development of bnAbs against the Env apex region (Doria-Rose et al., 2014) and of non-VRC01-class anti-CD4-BS bnAbs have been identified and characterized (Bonsignori et al., 2016; Liao et al., 2013) . Viral Envs associated with the maturation of VRC01-class antibody responses have also been reported in the case of chronic HIV-1 infection (Bonsignori et al., 2018; Lynch et al., 2015) , but such viral Envs were derived from samples collected after the VRC01 B cells lineages had already expanded. More recently however, Umotoy et al. (2019) reported on the longitudinal evolution of virus and VRC01-class B cell lineages in an HIV-1-infected patient from protocol C. So far, however, the natural Env(s) that initiated the production of VRC01-class antibodies during HIV-1 infection have yet to be identified. Also, the inferred germline forms of VRC01-class antibodies (commonly referred to as glVRC01 Abs), do not display detectable reactivity to diverse recombinant Env-derived soluble proteins Jardine et al., 2013; McGuire et al., 2013) . In recent years, we and others reported on the design of "germline VRC01-targeting" recombinant Env-derived proteins capable of binding glVRC01-class Abs McGuire et al., 2013 McGuire et al., , 2014 McGuire et al., , 2016 Medina-Ramírez et al., 2017) . A key feature of such immunogens is the absence of the conserved Nlinked glycosylation site (NLGS) at position 276 within loop D of the gp120 Env subunit, as the N276-associated glycans present a major barrier to glVRC01 Ab binding, through steric obstruction of the germline-encoded CDRL1s McGuire et al., 2013; Zhou et al., 2013) . Mature VRC01 bnAbs accommodate this glycan by either incorporating glycine residues in their CDRL1 domains or by shortening them during affinity maturation .
Although VRC01 germline-targeting immunogens activate B cells engineered to express glVRC01-class B cell receptors (BCRs) in vitro and in vivo McGuire et al., 2013 McGuire et al., , 2014 McGuire et al., , 2016 Medina-Ramírez et al., 2017) , these cells undergo limited somatic mutation and the secreted antibodies fail to bind in the presence of N276-associated glycans on wild-type (WT) Envs (Dosenovic et al., 2015; Jardine et al., 2015; . Efforts to guide the maturation of VRC01-like antibody responses elicited by germline-targeting immunogens through subsequent immunizations with heterologous Env-derived proteins also lacking the N276 glycans, led to increased somatic mutations, in both the VH and VL antibody genes, but no direct evidence that the elicited antibodies could accommodate N276-associated glycans was provided Tian et al., 2016) .
Here, we report on a two-step immunization scheme that begins with a prime immunization with the VRC01 germline-targeting prime immunogen, 426c Core, that lacks the N276 NLGS, followed by a boost immunization with a heterologous Env-derived immunogen, harboring the 276 NLGS. The outcome of this immunization scheme was the production of VRC01-like antibodies capable of accommodating the steric block imposed by the glycans present at N276 on heterologous gp120 Core-derived Envs and neutralizing the autologous, tier 2 426c virus with a modified glycan shield.
RESULTS

The 426c Core Germline-Targeting Immunogen Elicits Potent Plasma Antibody Responses against the VRC01 Epitope in Knockin Mice
We previously reported on the design of a recombinant protein derived from the inner and outer gp120 domains of the clade C Env 426c, lacking the variable domains 1, 2, and 3 as well as three NLGS at positions N276 (loop D), N460, and N463 (V5). That protein (TM4ΔV1-3, herein referred to as "426c Core" for simplicity) binds several of the known glVRC01-class Abs . Here, two nanoparticle forms of the 426c Core were employed as immunogens: a 5-to 7-meric form (426c Core C4b) (Hofmeyer et al., 2013; McGuire et al., 2016; Ogun et al., 2008) and a Ferritin-based 24-meric form (426c Core Fer) (Kanekiyo et al., 2013; McGuire et al., 2016) . One additional germline VRC01targeting immunogen was investigated for its ability to engage B cells expressing glVRC01 BCRs in vivo: the 426c DS-SOSIP D3 Joyce et al., 2017) . It is derived from the clade C 426c virus (like the 426c Core) and was modified by eliminating the above-mentioned three NLGSs. We also performed an immunization with the non-germline targeting unmodified 426c WT gp120 as a control.
As animal species, such as mice, rats, rabbits, or non-human primates do not express orthologs of the human VH1-2*02 allele Vigdorovich et al., 2016; West et al., 2012) , immunizations were performed in a knockin mouse that is heterozygous for the glVRC01 HC, whereas the LCs remain the endogenous mouse LCs (mLCs) . Approximately 80% of naive B cells express the glVRC01 HC and 0.1% of mLCs express 5-aa-long CDRL3s. Thus, the overall estimated frequency of naive B cells expressing potential glVRC01 BCRs in this mouse model is approximately 0.08% (compared to approximately 0.01% in humans; Arnaout et al., 2011; DeKosky et al., 2015; Jardine et al., 2015) . The elicitation of VRC01-class bnAbs in this model requires overcoming at least two major obstacles: first, the germline-targeting immunogen must select for the B cells expressing extremely rare mLCs with a 5-aa CDRL3 paired with the glVRC01 HC, and second, the immunization regimen must lead to the accumulation of mutations that will allow the maturing B cells to bypass the obstacles presented by the N276 glycans on full-length Envs.
A single immunization with either nanoparticle form of 426c Core with two different adjuvants (poly(I:C) or GLA-LSQ) elicits robust autologous plasma antibody responses ( Figure 1A) , the majority of which target the CD4-BS ( Figure 1B ). Plasma antibodies generated in approximately 77% of the 426c Core-immunized animals (66 of 85), also recognized the heterologous VRC01 germline-targeting immunogen eOD-GT8 ( Figure 1C ) in a VRC01 epitope-dependent manner (Figures S1A and S1B). eOD-GT8 is derived from the outer domain of the gp120 subunit of the clade B HxB2 Env . Thus, antibodies elicited by the 426c Core that recognize eOD-GT8, but not the eOD-GT8 knockout (KO) (not recognized by VRC01-class antibodies) are most likely VRC01 epitopespecific. In contrast, the 426c DS-SOSIP D3 germline-targeting immunogen elicited very weak autologous plasma antibody responses and only one animal elicited antibodies against the 426c Core, which were non-CD4-BS directed and did not recognize eOD-GT8 ( Figure  S1C ). Animals immunized with the non-germline-targeting Env 426c WT gp120 immunogen elicited strong autologous responses, but weak anti-426c Core antibody responses and no eOD-GT8 antibody response ( Figure S1D ).
We concluded that the 426c Core immunogen elicits potent anti-CD4-BS antibody responses, which recognize the VRC01 epitope.
426c Core Selects for Key Mutations in the Antibody HC and LCs
To directly demonstrate that the 426c Core expands VRC01-lineage B cells, 2 weeks after immunization, eOD-GT8 + /eOD-GT8 KO − specific class-switched B cells from the spleens and lymph nodes (LNs) of mice displaying plasma antibody cross-reactivity to eOD-GT8 were sorted and their VH/VL genes were sequenced. eOD-GT8 + /eOD-GT8 KO − B cells were also sorted from unimmunized animals (a summary of the sequence analysis is presented in Figure S2 ). A total of 420 eOD-GT8+/eOD-GT8 KO − class-switched B cells were singly sorted from the immunized animals and their VH and VL genes were amplified using PCR. 204 HC and 70 LCs were successfully sequenced ( Figures S2A and S2C ). 96% of HCs were VH1-2*02 ( Figures 1D and S2B ). In the majority (approximately 70%) of VH1-2*02 HCs isolated after the prime immunization, the histidine at position 35 in the CDRH1 domain was replaced by an asparagine ( Figure S4A ). The H35N mutation introduces an additional hydrogen bond with N100a in CDRH3 and increases the stability of interaction between CDRH1 and CDRH3 on VRC01-class antibodies .
Approximately 57% of mLCs contained 5-aa-long CDRL3s ( Figures 1E and S2E ). The majority of the 5-aa CDRL3s are derived from the mouse 8-30*01 LC V gene, which is represented at approximately 6% in the naive eOD-GT8 + /eOD-GT8 KO − B cell repertoire ( Figures 1F and S2D ). Other mLCs that utilized a 5-aa CDRL3 are derived from V-genes: 12-46*01, 4-61*01, 4-72*01, and 6-25*01 (representing 2.5% of the LC sequences with 5 aa each). All the identified 5-aa-long CDRL3s-containing mLCs were paired with glVRC01 HCs. Immunization with the 426c Core therefore preferentially expanded B cells expressing mLCs with 5-aa-long CDRL3s. A large fraction (40%) of the 5-aa-long CDRL3s contained a Glu96 LC ( Figures 1G and S2F ), which is a key feature of mature VRC01-class antibodies and forms a hydrogen bond with Gly459 gp120 at the N terminus of the V5 region (West et al., 2012; Zhou et al., 2013) . In contrast, 5-aa-long CDRL3s with Glu96 LC were not detected in the mLC sequenced from naive eOD-GT8 + /eOD-GT8 KO − B cells (Figures 1G and S2F) .
19 VH/VL pairs with VRC01 characteristics were expressed as IgGs (designated by "P" to indicate they were isolated following the prime immunization). All bound 426c Core and displayed no reactivity with 426c Core CD4-BS KO ( Figure 1H ). All 19 monoclonal antibodies (mAbs) also bound the eOD-GT8 protein, but not the eOD-GT8 KO ( Figure 1I ). As expected, the binding affinities of these antibodies for eOD-GT8 were higher than for 426c Core ( Figure S3 ).
A 3.6-Å resolution crystal structure of antibody P-p3b3 bound to the 426c Core and a 3.2-Å resolution crystal structure of antibody P-p1f1 bound to eOD-GT8 were solved ( Figure 2 ; Table S1 ). These antibodies bind 426c Core and eOD-GT8 with the same angles of approach that human glVRC01 binds 426c WT Core (all atoms root-mean-square deviation [RMSD] = 0.3 Å for gp120-Fv) or eOD-GT6 (all atoms RMSD = 0.8 Å for gp120-Fv) (Figure 2A ). Critical contacts, both in the HC ( Figure 2B ) and in the LC ( Figure 2C ), were maintained in these interactions: Trp50 HC , Asn58 HC , Arg71 HC , and Trp100B HC residues were not mutated in the mouse VRC01-like antibodies, adopted the same orientations, and participated in the same hydrogen bonding as observed with glVRC01 ( Figure 2B ). Similar to the human glVRC01 antibody, the short 5-aa CDRL3 of the mouse VRC01-like antibodies facilitates the interactions with gp120, and Glu96 LC maintains the hydrogen bonds with Gly459 and Asn280 of gp120. Only a few residues in the LC seem to contact the gp120, and they are located at the N terminus, CDRL1 and CDRL3 ( Figure 2C ). The mouse VRC01-like antibodies have longer CDRL1 than most human VRC01-class antibodies (17 versus 11-12 aa long based on the Kabat nomenclature); however, several human VRC01-class antibodies, including VRC01c-HuGL2, have been isolated by sorting naive B cells with eOD-GT8 that contain 17-aa-long CDRL1 whose sequence is similar to that of the VRC01-like antibodies identified here ( Figure 2C ) Jardine et al., 2016) . Whereas the shorter CDRL1 domain of the human inferred glVRC01 Ab is well ordered in the complex of this antibody with eOD-GT6 or with 426c WT Core , the CDRL1 of the mouse VRC01-like antibodies bound to 426c Core or eOD-GT8 and that of VRC01c-HuGL2 bound to eOD-GT8 were disordered, indicating extensive CDRL1 flexibility. Such flexibility is likely necessary to accommodate glycans present on N276 in the presence of longer CDRL1. We concluded that the 426c Core immunogen elicits antibodies with similar genetic and structural features of known human VRC01-class antibodies.
Antibodies Elicited by the 426c Core Neutralize the 426c Virus Lacking the N276-Associated Glycans
Eight of the above 19 mAbs were tested for binding to stabilized soluble trimeric Envs (SOSIP or NFL). None bound the autologous 426c WT DS-SOSIP ( Figure 3A) ; however, all bound to the derivative lacking the 276, 460, and 463 NLGS (426c DS-SOSIP D3) ( Figure  3B ), and seven bound the derivative only lacking the 276 NLGS (426c ΔN276 DS-SOSIP) ( Figure 3C ). Those seven mAbs also bound the heterologous 45_01dG5 NFL TD-2CC+(DS +) trimer ( Figure 3D ). 45_01dG5 Env is derived from a virus that circulated in patient 45, from which several VRC01-class antibodies have been isolated (including VRC01), and naturally lacks the 276 and 460 NLGS . mAb P-p1e7 did not bind to autologous or ΔN276 heterologous stabilized trimeric Envs and is the only antibody of those tested that lacks Glu96 LC ( Figure S4 ).
The neutralizing potency of four mAbs were evaluated against the WT 426c virus or its Δ276 NLGS derivative ( Figure 3E ) produced in either 293T or 293 GnTI −/− cells; viruses produced in 293 GnTI −/− cells can be used to detect the presence of glVRC01 class antibody neutralizing activities LaBranche et al., 2018) . In agreement with the binding data, the mAbs did not neutralize the WT 426c virus (regardless of whether it was produced in 293T or 293 GnTI −/− cells). However, three of four mAbs neutralized the GnTI −/− produced Δ276 NLGS virus, but not when produced in 293T cells. This could be due to the fact that the shorter glycans produced in the GnTI −/− cell line allow greater access of these still immature VRC01-like mAbs to the CD4-BS (LaBranche et al., 2018; Briney et al., 2016) . The fourth, non-neutralizing antibody, P-p1e7, is the one lacking Glu 96LC ( Figure  S4B ).
We concluded that the 426c Core immunogen elicits VRC01-like Abs that can recognize autologous and some heterologous soluble, stabilized Env trimers; avoiding clashes with variable regions 1, 2, and 3; and that the presence of Glu96 LC appears to be important for these interactions. However, although these antibodies can avoid the glycans present on the V5 Env region, their binding is impaired by the glycan at position N276 in Loop D.
Antibodies Elicited by the 426c Core Accommodate the N276 Associated Glycans on Heterologous Env Cores
Plasma antibodies from 426c Core-immunized animals displayed CD4-BS-dependent recognition of heterologous monomeric WT Core proteins derived from the HxB2 (clade B), 45_01dH1 (clade B), 93TH057 (clade A/E), Q168a2 (clade A), and QH0692 (clade B) Envs ( Figure S5A ). These gp120-derived proteins lack the variable domains 1, 2, and 3, but harbor the N-X-T/S sequons at position N276 and in the V5 loop ( Figure S5B ). This observation suggested that the VRC01-like antibodies elicited by the 426c Core may bind heterologous Env Core proteins even in the presence of the N276-associated glycans.
The binding of the above-mentioned VRC01-like mAbs was examined to both the monomeric and the multimeric (C4b-based) forms of these Cores (Figure 4 ). The mAbs exhibited very weak binding to the monomeric form of HxB2, but not the other WT Cores ( Figures 4A-4E ). However, seven of eight mAbs tested bound the multimeric forms of the HxB2 and 45_01dH1 WT Core proteins (P-p1e7 that lacks Glu 96LC did not bind) ( Figures  4F-4G ), and one mAb (P-p3b3) also bound the multimeric forms of 93TH057 WT Core ( Figure 4H ), Q168a2 WT Core ( Figure 4I ), and QH0692 WT Core ( Figure 4J ). Mature VRC01 strongly recognized both the monomeric and multimerized forms of these Cores, while germline VRC01 did not recognize either. Hence, the 426c Core-elicited VRC01 antibodies display intermediate binding phenotypes in comparison to those of the germline and mature human VRC01 mAbs.
We conclude that a single immunization with the 426c Core elicits VRC01-like antibodies that can bypass the N276 glycans on heterologous Envs as long as the variable domains are absent (i.e., gp120-Core forms).
A Heterologous Boosting Immunization Improves the Binding Affinities of VRC01-like Antibodies to Env
Based on the above observations, we hypothesized that a boosting immunization with a heterologous Core Env expressing glycans at position N276 may expand the population of B cells that are capable of bypassing the N276-associated glycans. To test this hypothesis, a new group of animals were immunized first with the C4b nanoparticle form of 426c Core and 4 weeks later with the C4b nanoparticle form of the HxB2 WT Core Env. Env-specific B cells were isolated from the spleens and LNs 2 weeks following the boost immunization and analyzed as described above. A total of 160 eOD-GT8 + /eOD-GT8 KO − B cells were isolated from these animals. 72 HCs and 79 LCs were successfully amplified and sequenced ( Figure  S2 ). The frequency of somatic mutation in the HC and LCs was higher in the antibodies isolated after the boost than after the prime ( Figures 5A and S4 ).
Fifteen antibodies (IgG) were generated from paired VH/VL sequences displaying VRC01class antibody features. These are designated by "B" to indicate they were isolated following the boost immunization. All mAbs recognized the 426c Core immunogen used during the prime in a CD4-BS-dependent manner ( Figure 6A ). They also bound eOD-GT8 in a VRC01 epitope-dependent manner ( Figure 6B ). While the VRC01-like antibodies elicited following the prime immunization displayed very weak binding to the monomeric HxB2 WT Core ( Figure 4A ), antibodies elicited after the boost, bound more strongly to several monomeric ( Figures 6C-6G ) and all multimeric WT Cores tested ( Figure S6 ). Overall, the VRC01-like antibodies isolated after the boost have more mutations in both their HCs and LCs ( Figure  5A ), and higher binding affinities ( Figures 5B and S7 ) than the antibodies isolated after the prime immunization.
One of the 15 antibodies (mAb B-p1b5) displayed binding to the 426c WT DS-SOSIP Env with an intact N276 glycan ( Figure 6H ). The binding was confirmed using negative stain (ns) electron microscopy (EM), where 1-3 Fabs can be observed bound per trimer ( Figure  6I ). A 3D nsEM reconstruction of 426c WT DS-SOSIP and B-p1b5 complex was generated in which coordinates of existing 426c DS-SOSIP D3 and glVRC01 (PDB: 6MYY) were fitted ( Figure 6J ) . Weak binding of a second mAb, B-p2e2, was also observed to the 426c WT DS-SOSIP Env. Importantly, out of the four mAbs tested for neutralization, B-p1b5 neutralized the WT 426c virus (IC 50 of 32.05 μg/mL) expressed in GnTI −/− cells ( Figure 6K ). The human germline VRC01 mAb does not neutralize this virus, suggesting that our mouse antibody is one step farther in the evolutionary pathway to VRC01. B-p1b5 also displays neutralizing activity against the heterologous tier 2 virus CH0505TF when produced in GnTI −/− cells, when the loop D-associated 276 NLGS is absent (Table S2 ). The virus lacking 197, 276, 362, and 461/462 was neutralized, but the virus lacking only 197, 276, and 362 was not (Table S2 ). The neutralizing activity of B-p1b5 was abrogated by the D279K mutation (Table S2) , as is the case for known human VRC01 antibodies suggesting that B-p1b5 recognizes the Env gp120 subunit in a VRC01-like manner . Thus, VRC01-like Abs isolated following the heterologous boost immunization have more mutations in their VH/VL domains, bind more efficiently to heterologous WT Core Envs than the antibodies isolated following the prime immunization with the 426c Core germline-targeting immunogen, and some also display autologous neutralization when the virus expresses Env with short glycans and heterologous tier 2 neutralizing activities, when certain NLGS surrounding the CD4-BS are absent. Thus, these antibodies have not yet matured sufficiently to become broadly neutralizing.
Vaccine-Elicited VRC01-like Antibodies Can Avoid Clashes with the N276-Associated Glycan
The results in the previous section suggested, but did not conclusively prove, that the VRC01-like Abs isolated following the prime and boost immunization with 426c Core and HxB2 WT Core could more efficiently circumvent the steric hindrance imposed by the glycan at position N276 than those antibodies isolated following the prime immunization with the "germline-targeting" 426c Core immunogen.
To address this point directly, we performed a series of complementary experiments. In one experiment, B-p1b5 was co-expressed in GnTI −/− cells with the 426c WT Core (which expresses the N-X-S/T sequon at position N276) as a disulfide cross-linked complex . The purified Ab-Env complex was further enzymatically treated with Endo H, and semiquantitative mass spectrometry analysis of the 276 NLGS was performed ( Figure  7A ). Man5 glycans were detected at position N276, confirming that B-p1b5 binds the 426c WT Core in the presence of N276-associated glycans. Despite the additional Endo H treatment following complex formation, no (GlcNAc) 1 glycopeptides were detected at the 276 NLGS by liquid chromatography-tandem mass spectrometry (LC-MS/MS). This observation validated that bound B-p1b5 antibody protected the N276 glycan from enzymatic digestion when interacting with its cognate epitope.
Additional experiments were performed to probe these interactions in the absence of disulfide cross-linking. In one such experiment, we used an N276-dependent mAb, 179NC75, to purify the N276-glycosylated HxB2 WT Core Env ( Figure 7B ). Purified monomeric HxB2 WT Core expressed in GnTI −/− cells was incubated with 179NC75 immobilized on magnetic beads and the bound Core molecules were eluted and tested for recognition by mouse VRC01-like antibodies N-p4a9 and N-p3g9, isolated from unimmunized animals; P-p3b3, isolated following the prime immunization; and B-p1a11 and B-p1b5, isolated following the boost immunization. As expected, the antibodies isolated from unimmunized animals did not display HxB2 WT Core reactivity ( Figures 7C  and 7D ). P-p3b3 displayed marginal reactivity to HxB2 WT Core molecules expressing N276 glycans ("enriched") ( Figure 7E ), while the two antibodies isolated after the boost, bound strongly to the HxB2 WT Core molecules expressing N276 glycans ("enriched") ( Figures 7F and 7G) .
In another set of experiments, monomeric 426c WT Core and HxB2 WT Core proteins expressed in GnTI −/− cells were incubated with magnetic beads coated with the abovementioned mouse VRC01-like antibodies. Following immunoprecipitation, the flow-through and eluted materials were subjected to gel electrophoresis ( Figures 7H and 7I ). As expected, neither 426c WT Core nor HxB2 WT Core proteins were immunoprecipitated by the N-p3g9 and N-p4a9 mAbs. 426c WT Core, but not HxB2 WT Core, was precipitated by P-p3b3. In contrast, both 426c WT Core and HxB2 WT Core were immunoprecipitated by B-p1b5. Semiquantitative mass spectrometry analysis was performed to determine the presence of Man5 glycans at position N276 in the immunoprecipitated material ( Figures 7J and 7K ). This analysis confirmed that the mouse VRC01-like antibodies isolated following the prime have the potential of recognizing 426c WT Core molecules expressing N276-associated glycans and that the antibodies isolated following the boost have the potential of recognizing both the 426c WT Core and HxB2 WT Core in the presence of N276 glycans. We note that these antibodies preferentially immunoprecipitated Env molecules lacking the N276associated glycans, a consequence of not yet being fully matured following the prime-boost immunization scheme.
Collectively, the above experiments confirm that the VRC01-like antibodies isolated following the boost immunization can accommodate N276-associated glycans on fully glycosylated heterologous gp120-derived Core proteins, but less so on trimeric Envs present on virions.
DISCUSSION
A major challenge to the successful maturation of the germline forms of VRC01 antibodies toward their broadly neutralizing forms is the steric hindrance imposed by glycan molecules present on the conserved loop D 276 NLGS. As the present germline-targeting Env-based immunogens are designed to specifically lack the 276 NLGS McGuire et al., 2013 McGuire et al., , 2014 McGuire et al., , 2016 Medina-Ramírez et al., 2017) , they are expected to preferentially activate BCRs that recognize the VRC01 epitope when N276-associated glycans are absent. Efforts to guide the maturation of such antibodies through sequential immunization with Env constructs also lacking 276 NLGS have so far met limited success Tian et al., 2016) . In the study by Tian et al., six different immunogens (only the fifth and sixth of which expressed N276-associated glycans) were sequentially administered in a knockin mouse model that expresses both the human IGHV1-2*02 and the germline human IGKV3-20*01 genes. mAbs isolated at the end of the immunization efficiently neutralized autologous 426c viruses lacking the N276 NLGS, and one antibody weakly neutralized the autologous 426c WT virus, which presumably had glycans occupying N276. The mechanism by which this mAb could bypass the N276-associated glycan was not reported (Tian et al., 2016) . The study by Briney et al. was conducted in the same animal model we employed here, which we consider to be more stringent than the one employed by Tian, as only the glVRC01 HC is knocked in. Thus, in this model, the immunogens must first activate the rare B cells that also express a VRC01-like LC; i.e., one with 5-aa CDRL3s. Three different immunogens were administered sequentially, all three lacking N276-associated glycans. The antibodies isolated at the end of immunization efficiently neutralized heterologous viruses lacking N276-asociated glycans, and one antibody neutralized a tier 2 heterologous virus, although it is unclear whether all the virionassociated Envs express N276-associated glycans and whether and how this particular antibody bypassed the N276 glycan on this virus but not on the other viruses tested ).
Here, we tested an alternative immunization scheme during which the prime immunization with the 426c Core germline-targeting immunogen is immediately followed by an immunization with a heterologous Core that expresses N276-associated glycans. This scheme was selected because we observed that a fraction of the VRC01-like antibodies elicited by the 426c Core immunogen display weak binding to heterologous Cores with N276 glycans. Indeed, the boost immunization improved the ability of the elicited VRC01like antibodies to bypass the N276-associated glycans. Our observations are in agreement with reports by Escolano et al. (2016 Escolano et al. ( , 2019 , where germline PGT121 BCRs were activated upon immunization with very low-affinity Env-derived immunogen.
The 426c Core immunogen selects for VRC01-like antibodies with key features. The H35N mutation in the CDRH1 domain leads to an increased stability between the CDRH1 and CDRH3 domains of the HC, whereas the selection of the Glu96 LC allows for the formation of a hydrogen bond with Gly459 gp120 at the N terminus of the V5 region (West et al., 2012; Zhou et al., 2013) . Our data indicate that, within the 5-aa-long CDRL3 domains, the presence of Glu96 LC appears to be important for the antibody interactions with autologous and heterologous Core proteins. LCs with 5-aa-long CDRL3s are identifiable from naive B cells in this mouse model. However, we have not yet identified LCs with 5-aa-long CDRL3 containing a Glu96 LC in the BCR repertoire analysis of naive B cells from the unimmunized mice. Either these LCs are present at extremely low frequencies and our germline-targeting immunogen selects for them, or Glu96 LC is the result of somatic hypermutation (SHM) and subsequent selection in the germinal center following immunization with the 426c Core immunogen.
The majority of mouse VRC01-like antibodies elicited by the 426c Core, and which were subsequently boosted by the HxB2 WT Core, express LCs derived from the mouse k8-30*01 VL gene ( Figures 1C and S4B) , similar to what was previously reported during eOD-GT8-based immunizations in this same mouse model Jardine et al., 2015) . As a result, their CDRL1 are 17 aa's long (Figures 2 and S4B ). Most mature human VRC01 mAbs express shorter CDRL1s (7-11 aa long, per Kabat numbering), which sometimes contain flexible glycine residues . These CDRL1 features are believed to be necessary for the antibody LCs to accommodate the N276-associated glycans . However, several glVRC01-class antibodies isolated from naive B cells using eOD-GT8 as a bait express longer CDRL1s . One of them, VRC01c-HuGL2, recognizes eOD-GT8 in a manner similar to mature VRC01 and has a CDRL1 almost identical in aa sequence as the one present in the mouse VRC01 antibodies described here ( Figure 2) .
As compared to the rest of the VL domains, the CDRL1 regions appear to be under intense selective pressure to accumulate negatively charged aa's ( Figure S4B ). For instance, in most sequences, Lys30 LC is replaced by a glutamic acid and additional negatively charged aa's (Asp or Glu) are also introduced in that same general region of CDRL1. Although we were able to confirm that the mouse VRC01-like antibodies elicited by our vaccination strategy recognize the VRC01 epitope in the presence of N276-associated glycans, the disordered CDRL1 structures limit our understanding on how the introduction of negatively charged aa's allow these LCs to accommodate these glycans. Affinity maturation of the antibodies outside of the CDRL1 region may have compensated for the entropic cost of binding in the presence of the N276-associated glycan as has been observed in the VRC08 antibody lineage, which has a long rigid CDRL1 (Bonsignori et al., 2018) . VRC01-like antibodies that do not express k8-30*01-derived VL domains were also isolated after the prime immunization ( Figure S4B ). These express shorter CDRL1 domains (10-11 aa's), but in contrast to the k8-30*01-expressing antibodies, they were not mutated from germline, nor did they contain Glu96. So far, the neutralizing activities of mAbs isolated following the prime-boost immunization are evident against the 426c-derived virus lacking the 276 NLGS and against the heterologous CH0505TF-derived virus that not only lacks the N276 NLGS but also V5-associated NLGS (positions 461/462) ( Table S2 ). The observation that the D279K mutation abolished the neutralizing activity of mouse VRC01-like antibodies indicates that this activity is indeed targeting the VRC01 epitope. In that case, the absence of V5-associated NLGS appears to be required for neutralization. In all cases, the potency of neutralization was higher when the target virus was expressed in 293 GnTI −/− cells, an indication that the mouse VRC01-like antibodies have not yet accumulated the necessary mutations to accommodate complex glycans surrounding the CD4-BS. Presently, it is unknown whether further maturation of the mouse VRC01-like antibodies toward their broad neutralizing activities will be delayed by the presence of long CDRL1 domains.
Although approximately 0.08% of B cells express germline VRC01-like BCRs in the mouse model employed here (as compared to approximately 0.01% in humans), approximately 80% of the B cells express the already rearranged VDJ germline HC VRC01 chain . It will therefore be important to evaluate the prime-boost immunization protocol discussed here, at more physiological frequencies of target B cells. Such experiments would most likely require adoptive transfer of target B cells into a wild-type animal, as recently reported (Abbott et al., 2018; Dosenovic et al., 2018) .
The data presented here inform how VRC01-class antibody responses may be generated during natural HIV-1 infection. It suggests that although viral Env species that initiated the expansion of precursor VRC01-class BCRs in the context of infection may either lack N276associated glycans or have short N276-associated glycans, the subsequent viral Envs that guide the maturation of these antibodies to bypass the N276-associated glycans most likely express glycans at N276. Indeed, sequence analysis of viral Envs in patient 45 , from which VRC01 was isolated from , indicate the early presence of viral variants lacking N276-associated glycans, which were gradually replaced by viral Env variants expressing N276-associated glycans. Also, the recent report by Umotoy et al. (2019) suggests that in the context of HIV-1 infection the development of VRC01 bnAbs may benefit from an early B cell response to Envs with N276-associated glycans. In this last study, VRC01-class lineages with preferred reactivity in the presence of N276-associated glycans were also identified.
Our study informs on how to guide the maturation of glVRC01-class antibodies during immunization, so that the immunogens employed during the boost select for antibodies with mutations that allow them to accommodate the N276-associated glycan. As such, our results are relevant to current and upcoming clinical trials that evaluate the ability of germlinetargeting immunogens to elicit cross-reactive VRC01-class antibody responses.
STAR★METHODS LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for reagents should be directed to and will be fulfilled by Leonidas Stamatatos (lstamata@fredhutch.org). All reagents generated in this study can be made available upon request through Materials Transfer Agreements.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Immunizations were performed in the glH-VRC01 mouse . It is heterozygous for the transgene (glVRC01 HC with the CDRH3 found in the mutated antibody) and only expresses mouse light chains. The Fred Hutch Institutional Animal Care and Use Committee approved all mouse studies. Mice were 6-12 weeks old at the beginning of the studies. Both male and female mice were included in these studies. Mice were immunized intramuscularly with a dose of 60 ug of protein and 60 ug of poly(I:C) (InvivoGen, Cat# tlrl-pic-5) split between the rear hind legs or with 50 ug of protein and 50 ul of GLA-LSQ (IDRI). Blood was collected retro-orbitally during immunization and via a cardiac puncture 2 weeks following the last immunization, at which time spleen and LNs were also harvested. Spleen and LNs were processed into a single cell suspension separately, frozen in FBS + 10% DMSO and stored in liquid nitrogen until further use. Blood, spleens and LNs were also isolated from non-immunized animals.
METHOD DETAILS
Protein expression and purification-Recombinant Env proteins expressed in nanoparticle (Ferritin or C4b-based) and NFL forms were expressed and purified as previously described (Guenaga et al., 2015; McGuire et al., 2016) . Briefly, Envs were produced in 293E or 293F. Cell supernatants were purified by lectin affinity chromatography (Galanthus nivalis, Vector Labs), then subjected to Superdex 200 size exclusion chromatography (GE Healthcare). Ferritin nanoparticles underwent two rounds of size exclusion chromatography, first on a Superose 6 10/300GL column and then on a HiLoad 16/600 Superdex 200pg column.
Soluble trimeric SOSIP-based Envs were expressed and purified as previously described . In short, Env-expressing and furin-expressing plasmids were cotransfected (at 5:1 DNA ratio) into 293E cells. The Envs were purified from the cell supernatants using a Ni-affinity column followed by a Streptactin affinity column. Proteins were then subjected to enzymatic cleavage to remove the his-tag.
Monomeric proteins were produced by transfecting 293E or GnTI−/− cells with Env encoding plasmid. Cells are cultured for 6 days at 37°C, 5% CO 2 , 80% humidity, and shaking at 125 RPM. Cells were centrifuged for 3000 RPM for 30 minutes and the supernatant sterile filtered through at 0.22 uM filter. Protein was purified by passing the cellular supernatant over a 5ml Fast Flow HisTrap column (Fisher Sci, Cat # 45000326). The eluted protein was purified on SEC as described above.
cDNA was diluted 1:2. Two rounds of PCR were employed to amplify both VH and VL genes. Each PCR reaction contains: 7 ul of cDNA, 2.4 units of HotStar Taq Plus (QIAGEN, Cat#: 203607) , 240 nM of 5′ and 3′ primer, 350 uM GeneAmp dNTP Blend (Thermo Fisher Scientific, Cat#: N8080261), 4 ul of 10X buffer, and 27.8 ul nuclease free H 2 0. All primers and cycling conditions can be found in Tables S3 and S4 . After the second round of PCR, samples were subjected to electrophoresis on a 1.5% agarose gel containing 0.1% Gel Red Nucleic Acid Stain (Biotium, Cat#: 41002). cDNA was purified using the enzyme ExoSap-IT (Affymetrix, Cat#: 78201). The purification reaction contained 5 ul of second round PCR product and 2 ul of ExoSap-IT. This reaction was run on a thermocycler for 15 min at 37°C followed by 15 min at 80°C. Following enzymatic purification, 5 ul of 5 uM second round 5′ primer was added to the sample and 3 ul of nuclease free water. Samples underwent sanger sequencing to identify the DNA sequence (Genewiz, Seattle, WA). Upon receiving the sequence, IMGT/V-QUEST was used to assign V, D, and J gene identity to the sequences and CDRL3 length (Brochet et al., 2008; Giudicelli et al., 2011) . Sequences were included in the analysis ( Figure S2 ) if they had an identifiable CDR3 region.
Amino acid mutations were identified by aligning the VH/VL gene sequences to the corresponding germline genes (IMGT Repertoire) using the Geneious Software (Version 8.1.9). For VL, mutations were counted beginning at the 5′ end of the V-gene to the 3′ end of the FW3. For VH, mutations were counted beginning at the 5′ end of the V-gene to the end of the KI gene. See Figure S4 for sequence alignments. To quantify the number of amino acid mutations, the sequence alignments were exported from Geneious and imported into R (Version 3.4.1) for analysis (R Core Team, 2018) . This analysis uses the packages Biostrings (Pages et al., 2018) , seqinr (Charif and Lobry, 2007) , and tidyverse (Wickham, 2017) . The sequences and code for this analysis can be found here: https://github.com/ krparks/glVRC01_sequential_immunization. VH and VL cloning and antibody expression-Gene-specific PCR was used to amplify the DNA product from the first round PCR using primers designed to anneal to the gene of interest as well as add ligation sites to facilitate insertion of the DNA fragment into the human IgG1 vector [ptt3 k for kappa , and PMN 4-341 for gamma (Mouquet et al., 2010) ]. Each gene specific PCR reaction contained 0.5 ul each of 10 uM 5′ and 3′ primer, 22.5 ul Accuprime Pfx Supermix (Cat#: 12344040), and 1.5 ul of 1 st or 2 nd round PCR product. The gene-specific PCR product was infused into the cut IgG1 vector in a reaction containing 12.5 ng of cut vector, 50 ng of insert, 0.5 ul of 5X Infusion enzyme (InFusion HD Cloning Kit, Cat#: 639649), and nuclease-free water to bring volume to 2.5 ul. The entire reaction was used to transform competent E. coli cells and plated on agar plates containing ampicillin. In some cases, gBlocks were synthesized to make the VH or VL containing plasmid (GenScript). 60 ng of glBlock was added to 15 ng of cut vector and 0.5 ul of 5× In-Fusion enzyme (Takara, Cat#: 1805251A). This reaction was run on the thermocycler for 15 min at 50°C. The entire reaction was used to transform competent E. coli cells (New England Biolabs, Cat#: C2987HI) and plated on agar plates containing ampicillin. Once a colony containing the insert sequence was identified, it was grown in LB broth containing ampicillin. DNA was prepared using QIAprep Spin Miniprep Kit (QIAGEN, Cat#: 27106) . Equal amounts of heavy and light chain DNA and 293F transfection reagent (Millipore Sigma, Cat#: 72181) were used to transfect 293E cells. 5-7 days post transfection cell supernatants were collected, and the antibodies were purified using Pierce Protein A agarose beads (Thermo Fisher Scientific, Cat#: 20334) . The antibodies were eluted using 0.1 M Citric Acid into a tube containing 1 M Tris. The antibodies were buffer exchanged into 1XPBS using an amicon centrifugal filter.
To make Fabs, the IgG was cleaved overnight at 37°C to generate antigen binding fragment (Fab) with Endoproteinase Lys-C (NEB). To remove undigested IgG and IgG Fc fragments, the mixture was incubated with Protein A Agarose Resin for 1 hour at room temperature. Beads were washed with 1X PBS to remove excess Fab. Fab was further purified on SEC using a HiLoad 16/600 Superdex 200 pg (GE) column.
Ammonium Citrate pH 5.5. P-p1f1fab + eODGT8 crystal were cryo protected in a solution of 20% molar excess of the crystallization condition and 20% Ethylene Glycol. P-p3b3fab + 426c Core were cryoprotected in the original crystallization condition. P-p3b3fab + 426c Core and P-p1f1fab + eODGT8 were sent to ALS 5.0.2 and diffraction data was collected to 3.59 Å and 3.2 Å respectively. Data were processed using HKL2000 (Otwinowski and Minor, 1997) .
Structure Solution and Refinement-The structure of P-p1f1Fab + eOD-GT8 was solved by molecular replacement using PDB ID: 4JPK as a search model in Phaser in Phenix. The structure of P-p3b3Fab + 426c Core was solved by molecular replacement using PDB ID: 6MFT as a search. The structures were further refined with COOT (Emsley and Cowtan, 2004) and Phenix (Adams et al., 2004) . The refinement statistics are summarized in Table S1 .
Negative-stain EM-The 426c WT DS-SOSIP/B-p1b5 complex was formed by coincubating B-p1b5 Fab to 426c WT DS-SOSIP trimer at a 2:1 B-p1b5:gp120 monomer ratio (alternatively referred to as 6:1 B-p1b5 trimer ratio) ratio for 10 minutes at 4°C. Samples treated with glutaraldehyde were cross-linked in 0.25% GTA for 45 s followed by quenching with 1M Tris, followed by purification of bound complexes via a Superdex 200 10/300 GL Increase column. 426c WT DS-SOSIP/B-p1b5 Fab complexes examined in this study (3 μL) were negatively stained at a final concentration of 0.010 mg/mL using Gilder Grids overlaid with a thin layer of carbon and 2% uranyl formate (Electron Microscopy Sciences, Cat#: 22451) as previously described (Veesler et al., 2014) .
Data were collected on an FEI Technai 12 Spirit 120kV electron microscope equipped with a Gatan Ultrascan 4000 CCD camera. A total of ~300 images were collected per sample by using a random defocus range of 1.1-2.0 μm with a total exposure of 45 e−/A 2 . Data were automatically acquired using Leginon (Suloway et al., 2005) and data processing was carried out using Appion (Lander et al., 2009) . The parameters of the contrast transfer function (CTF) were estimated using CTFFIND4 (Mindell and Grigorieff, 2003) , and particles were picked in a reference-free manner using DoG picker . Particles were extracted with a binning factor of 2 after correcting for the effect of the CTF by flipping the phases of each micrograph with EMAN 1.9 (Ludtke et al., 1999) . The GTA cross-linked 426c WT DS-SOSIP B-p1b5 Fab stack was pre-processed in RELION/2.1 (Kimanius et al., 2016; Scheres, 2012a Scheres, , 2012b with an additional binning factor of 2 applied, resulting in a final pixel size of 6.4 Å. Resulting particles were sorted by reference-free 2D classification over 25 iterations. The best particles were chosen for 3D classification into 2 classes using C1 symmetry in RELION/2.1 (Kimanius et al., 2016) . The best class of particles were refined using Relion/3.0 (Zivanov et al., 2018) .
Biolayer Interferometry (BLI)-Antibody binding to recombinant Env proteins was determined using biolayer interferometry on the Octet Red 96 (ForteBio, Inc, Menlo Park, CA), as previously described . Briefly, anti-human Fc capture biosensors (ForteBio, were activated by immersion into 1× Kinetics Buffer (1× PBS, 0.1% BSA, 0.02% Tween-20, 0.005% NaN 3 ) for 10 minutes. Antibodies were loaded onto an anti-human Fc capture probe at 20 ug/ml. The probes were then dipped into Cat#: 6066766). Neutralization titers are the antibody concentration at which relative luminescence units (RLU) were reduced by 50% compared to RLU in virus control wells after subtraction of background RLU in cell control wells.
Immunoprecipitation-Purified recombinant IgGs were covalently coupled to MyOne Tosylactivated Dynabeads (Thermo Fisher Scientific, Cat#: 65501). Coupling and Envimmunoprecipitation were carried out according to the manufacturer's protocol. Briefly, 5 mg of Env produced in HEK293S GnTI −/− were incubated with 200 μg of IgG-beads for 30 min. The IgG-Env protein complexes were then precipitated using magnetic separation and washed 3-4× before performing acidic elution and pH neutralization of the bound material. Env-samples of the original input of 426c WT Core or HxB2 WT Core, and bead-bound/ eluted and unbound fractions were subjected to SDS gel electrophoresis under reducing conditions. A sample of the bound fractions were subjected to LC-MS/MS analysis or used for BLI.
Mass spectrometry-For analysis of the N-linked glycosylation profile of the crosslinked 426c WT Core-P1B5 complex, 250 pmol of sample was denatured, reduced, and alkylated by dilution to 5 μM in 50 μL of buffer containing 100 mM Tris (pH 8.5), 10 mM Tris (2-carboxyethylphosphine (TCEP), 40 mM iodoacetamide or 40 mM iodoacetic acid, and 2% (wt/vol) sodium deoxycholate. Samples were first heated to 95°C for 5 min and then incubated for an additional 25 min at room temperature in the dark. The samples were digested with trypsin (Thermo Fisher Scientific, Cat#: 90057), by diluting 20 μL of sample to a total volume of 100 μL of buffer containing 50 mM ammonium bicarbonate (pH 8.5). Trypsin was added in a ratio of 1:50 (w/w) before incubation at 37°C overnight. Subsequently, 2 μL of formic acid was added to precipitate the sodium deoxycholate from the solution. Following centrifugation at 17,000 × g for 25 min, 85 μL of the supernatant was collected and centrifuged again at 17,000 × g for 5 min to ensure removal of any residual precipitated deoxycholate. 80 μL of this supernatant was collected. For each sample, 8 μL was injected on a Thermo Scientific Orbitrap Fusion Tribrid mass spectrometer. A 35 cm analytical column and a 3 cm trap column filled with ReproSil-Pur C18AQ 5 μM (Dr. Maisch) beads were used. Nanospray LC-MS/MS was used to separate peptides over a 90 min gradient from 5% to 30% acetonitrile with 0.1% formic acid. A positive spray voltage of 2100 was used with an ion transfer tube temperature of 350°C. An electron-transfer/higherenergy collision dissociation ion-fragmentation scheme (Frese et al., 2013) was used with calibrated charge-dependent entity-type definition parameters and supplemental higherenergy collision dissociation energy of 0.15. A resolution setting of 120,000 with an AGC target of 2 × 10 5 was used for MS1, and a resolution setting of 30,000 with an AGC target of 1 × 10 5 was used for MS2. Data were searched with the Protein Metrics Byonic software (Bern et al., 2012) , using a small custom database of recombinant protein sequences including the proteases used to prepare the glycopeptides. Reverse decoy sequences were also included in the search. Specificity of the search was set to C-terminal cleavage at R/K (trypsin), allowing up to three missed cleavages, with EthcD fragmentation (b/y-and c/ztype ions). We used a precursor mass and product mass tolerance of 12 ppm and 24 ppm, respectively. Carbamidomethylation of cysteines was set as fixed modification, carbamidomethylation of lysines was set as a variable modification, methionine oxidation as variable modification, and a concatenated N-linked glycan database (derived from the four software-included databases) was used to identify glycopeptides. All analyzed glycopeptide hits were manually inspected to ensure their quality and accuracy.
Semiquantitative LC-MS/MS of P-p3b3, B-p1b5 and VRC01-immunoprecipitation experiments were performed using Skyline (MacLean et al., 2010) with peak integration and LC-MS/MS searches imported from Byonic, as previously described . Missed cleavages and post-translational modifications listed above for qualitative LC-MS/MS searches were included in the quantification of glycopeptides. All MS1 peak areas used for integration were manually inspected. Each fraction was performed as part of two technical replicates and was subsequently averaged. Calculations and plots for glycoform enrichment graphs were generated by subtracting the relative signal values of the input Core fraction from the unbound or bound Core fractions.
QUANTIFICATION AND STATISTICAL ANALYSIS
Mean and standard deviations were calculated using R (Version 3.4.1). Statistical analyses were calculated using R (Version 3.4.1) (R Core Team, 2018) and GraphPad Prism. Descriptions of the statistical methods used for each dataset are described in the figure legends. The tidyverse packages (Wickham, 2017) were used in R to manipulate data and create graphs in addition to GraphPad Prism.
DATA AND CODE AVAILABILITY
The sequences of mAbs reported here have been deposited on GenBank and in the GitHub respository: https://github.com/krparks/glVRC01_sequential_immunization. The accession numbers of the mAb sequences are GenBank: MN087228 -MN087315 (Table S5 ). Multimeric and monomeric heterologous Env sequences have been deposited on GenBank, accession numbers GenBank: MN179660-MN179671 (Table S5 ). Coordinates and structure factors have been deposited on the Protein Data Bank under PDB: 6P8N and PDB: 6P8M. Raw and analyzed Mass Spectrometry data have been deposited on PRIDE. The accession number for the mass spectrometry data is PRIDE: PXD015168.
Highlights
•
The germline-targeting 426c Core immunogen elicits cross-reactive VRC01like Abs
Boosting with HxB2 WT Core improves the neutralizing potential of VRC01like Abs (B) Summarizes the data from one experiment with 10 animals in each group. A paired t test was used to determine statistical significance between the mean EC 50 titers against the 426c Core versus those against its CD4-BS KO.
(C) Summary of the animal frequencies per group of 426c Core-immunized animals that developed anti-eOD-GT8 plasma antibody responses (OD 450 nm of ≥ 0.1 at 1:10 dilution; additional information is provided in Figure S1 ). The nanoparticle form and the adjuvant used is indicated. The number of animals that developed anti-eOD-GT8 responses out of the total immunized for each group is indicated within each bar. (G) Presence or absence of Glu96 LC within the LC sequences with 5-aa-long CDRL3 domains. mAbs with VRC01 characteristics were generated from paired VH/VL sequences from class-switched B cells isolated following the prime immunization (indicate by "P") with the 426c Core.
(H) mAb binding to monomeric 426c Core (colored lines) and to monomeric 426c Core CD4-BS KO (gray lines). (I) mAb binding to monomeric eOD-GT8 (colored lines) and to monomeric eOD-GT8 KO (gray lines). Data are representative of 1-2 experiments.
Figure 2. Structural Information of VRC01-like Antibodies Isolated after Immunization with the 426c Core Env
(A) Structures of P-p1f1 (shades of blue) in complex with eOD-GT8 (green) and P-p3b3 (shades of pink) in complex with 426c Core (gray) are shown in cartoon representation (left). These two structures are superimposed onto the structure of glVRC01 (shades of yellow) bound to 426c WT Core (orange) (PDB: 6MFT) (right). The structures are shown in ribbon representation and only the Fv portion of the Fab is shown for clarity. The glycan present at N276 in the structure of 426c WT Core bound to glVRC01 is shown in stick. (B) Zoom insets of important contact residues in the HC of glVRC01 and VRC01-like mouse antibodies. HC sequence alignments of glVRC01, P-p1f1, P-p3b3,and VRC01c-HuGL2. Residues within 5 Å of each respective antigen are shown with an asterisk under the alignment.
(C) LC sequence alignments of glVRC01 (k3-20), P-p1f1, P-p3b3, and VRC01c-HuGL2. Residues within 5 Å of each respective antigen are shown with an asterisk under the alignment. Zoom insets of the LC N terminus, CDRL1 and CDRL3 contacts. The glycan at N276 present in the structure of glVRC01 bound to 426c WT Core is shown in sticks (PDB: 6MFT). Disordered CDRL1s are drawn in dotted lines. VH/VL Mutations and Binding Affinities of VRC01-like Antibodies Isolated throughout the Immunization (A) The number of aa mutations per each VH and VL domains in mAbs generated from sequences isolated following the prime immunization with 426c Core and the boost immunization with HxB2 WT Core are shown (see Figure S4 for VH and VL sequence alignments). Each dot represents a sequence. A Welch two-sample t test (unpaired t test) was used to determine the statistical significance. Error bars show SD from the mean. (B) The binding affinities of antibodies (Fabs) isolated from naive, non-immunized animals (red) and antibodies generated after the prime immunization (blue) and following the boost immunization (green) are shown for the 426c WT Core and the HxB2 WT Core (binding traces and summary affinity information are shown in Figure S7 ). 
